
-
Bolsonaro discussed 'state of siege' after election loss: court told
-
US Open venue to get $800 mln facelift: officials
-
Brazil's ousted football president paves way for succession
-
Trump fuels Biden cancer cover-up claims
-
Rio Tinto invests in major Chilean lithium project
-
Guardiola to decide on Grealish future at end of season
-
Britain, Canada, France warn Israel over 'egregious' Gaza tactics
-
Path cleared for WHO assembly to adopt pandemic agreement
-
Liverpool rocked by Brighton's late fightback
-
US stocks edge higher while dollar dips after Moody's downgrade
-
Rihanna, A$AP Rocky watch Denzel Washington award in Cannes
-
Actors' union sues Fortnite over AI Darth Vader
-
Trump signs bill outlawing 'revenge porn'
-
CBS News boss resigns amid tensions with Trump admin
-
Eagles sign coach Sirianni to 'multi-year' extension
-
Trump seeks 'major' probe of celebs who backed Harris
-
Prosecutors focus on pattern of violence as Sean Combs trial continues
-
S.Africa says talks with Trump aim to salvage trade
-
After Putin call, Trump says Ukraine talks to start 'immediately'
-
How Biden cancer diagnosis could have gone undetected
-
UEFA move to defuse anger over Infantino delay at FIFA Congress
-
Biden thanks supporters for 'love' after cancer diagnosis
-
Abhishek blitz knocks Lucknow out of IPL play-off race
-
Italian designer Piccioli named creative director at Balenciaga
-
US top court allows lifting of legal protections for Venezuelans
-
Six Nations 2026 to start on Thursday to avoid Winter Olympics clash
-
El Salvador arrests rights lawyer helping deported migrants
-
Biden cancer diagnosis fuels Trump team's cover-up claims
-
Bolsonaro's trial on coup charges to begin in Brazil
-
Young Cameroonians face prospect of new bid by 92-year-old leader
-
Ex-Tour champion Vingegaard against 'stressful' Montmartre inclusion
-
Cairo-set Cannes thriller takes aim at Egypt's president
-
Nigeria needs good fathers, says director who made Cannes history
-
WHO guiding body gets to grips with budget beset by US pullback
-
Trump targets Beyonce in rant about endorsing Kamala Harris
-
AI talking trees feature at Chelsea Flower Show
-
Monkeys kidnap babies of another species in weird 'fad'
-
UK man gets two-year suspended term for gold toilet theft
-
The battle by Chile torture site dwellers to remain
-
ICJ sides with E.Guinea in spat with Gabon over oil-rich islands
-
Kevin Spacey to get charity award in Cannes despite new scandal
-
Pope meets Vance ahead of Ukraine ceasefire push
-
How serious is Biden's prostate cancer diagnosis?
-
Perrier scandal bubbles up as French parliament slams cover-up
-
Gary Lineker: England's World Cup hero turned BBC's 'defining voice'
-
Failure means Man City would not 'deserve' Champions League: Guardiola
-
Joe Biden thanks supporters for 'love' after cancer diagnosis
-
Three things we learned from the Emilia Romagna Grand Prix
-
Gary Lineker to leave BBC after antisemitism row
-
Serie A title deciders to be played Friday

AstraZeneca moves some production to US amid tariff threat
British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.
"Our company is firmly committed to investing and growing in the US," chief executive Pascal Soriot said in an earnings statement, which also reported that first-quarter profit rose by over 30 percent to $2.92 billion.
The United States earlier in April opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to Trump's sweeping levies on imports from trading partners.
Trump has also imposed a series of sector-specific levies, slapping tariffs on imports of steel, aluminium and autos, before launching a "national security" investigation into pharmaceutical imports.
AstraZeneca could become exposed to US levies on its European-made products but Soriot stressed that the impact would be limited due to the ongoing shift in production.
"The limit of the exposure we have relates to exporting products from Europe to the US," Soriot said on an earnings call.
"We are in the process of shifting the manufacturing of those products to the US," he added.
The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 billion there by the end of 2026.
Soriot said earlier in the year that he hoped the US will account for around half of AstraZeneca's global revenue by 2030.
Other pharmaceutical companies have also announced plans to increase investments in the United States.
AstraZeneca reconfirmed its outlook on Tuesday, saying it remains on track to achieve its target of $80 billion in annual revenue by the end of the decade.
Its first-quarter profit in 2025 benefited from strong growth in its cancer drug sales and biopharmaceuticals.
During the quarter, it generated 42 percent of its revenue in the United States, followed by 20 percent in Europe.
G.Haefliger--VB